author-photo

Noriyuki Namba

Osaka University

78

Papers

1657

Citations

Citation Trend

Filter By

Papers (56) Sort By

Journal Conference Others

Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia

2021 Calcified Tissue International
Show All
- Source
- Cite
- Save
Citations (3)
Mutation Fuzzing Based on Type Estimation of Data Items Utilizing Data Writer

2020
Show All
- Source
- Cite
- Save
Citations (0)
IGF2 MutationsReport of Five Cases, Review of the Literature, and Comparison with H19/IGF2:IG-DMR Epimutations

2020 The Journal of Clinical Endocrinology and Metabolism
Show All
- Source
- Cite
- Save
Citations (10)
Monthly intravenous alendronate treatment can maintain bone strength in osteogenesis imperfecta patients following cyclical pamidronate treatment.

2020 Journal of Pediatric Endocrinology and Metabolism
Show All
- Source
- Cite
- Save
Citations (0)
OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH)

2019 Journal of the Endocrine Society
Show All
- Source
- Cite
- Save
Citations (0)
Long-term growth hormone treatment alters glucose metabolism in achondroplasia

2019 Bone Abstracts
Show All
- Source
- Cite
- Save
Citations (0)
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial

2019 The Lancet
Show All
- Source
- Cite
- Save
Citations (97)
Burosumab Resulted in Better Clinical Outcomes Than Continuation with Conventional Therapy in Both Younger (1-4 Years-Old) and Older (5-12 Years-Old) Children with X-Linked Hypophosphatemia

2019
Show All
- Source
- Cite
- Save
Citations (0)
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial

2019
Show All
- Source
- Cite
- Save
Citations (0)
Burosumab resulted in greater improvement in clinical outcomes than continuation with conventional therapy in younger (1-4 years-old) and older (5-12 years-old) children with X-linked hypophosphatemia

2019 Bone Abstracts
Show All
- Source
- Cite
- Save
Citations (0)